Ark Invest Rotates Into Genomics and Large-Cap Tech, Trims Crypto Exposure

Ark Invest has executed a series of strategic reallocations across its active ETF portfolios, signaling a tactical shift toward specific high-growth sectors. The recent activity highlights a preference for genomics and fintech infrastructure, alongside a selective approach to large-cap technology. In a move to diversify its growth bets, the firm added positions in Alamar, a company specializing in proteomics, and the streaming giant Netflix. These acquisitions suggest a renewed focus on the intersection of advanced biotechnology and established digital entertainment platforms. Conversely, Ark has scaled back its exposure to cryptocurrency-linked assets. While the volume of trades remained relatively contained during the most recent week, the directional shift indicates a rotation away from digital asset volatility in favor of tangible biotech and tech platforms. These adjustments reflect Ark's ongoing strategy of active management, pivoting between disruptive innovation themes as market conditions and valuations evolve.